Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers

References

• MellmanICoukosGDranoffGCancer immunotherapy comes of ageNature2011480737848048922193102
   PubMed Web of Science ®Google Scholar
• EggermontAMChiarion-SileniVGrobJJAdjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialLancet Oncol201516552253025840693
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar
• RobertCSchachterJLongGVKEYNOTE-006 investigatorsPembrolizumab versus ipilimumab in advanced melanomaN Engl J Med2015372262521253225891173
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• RibasAPuzanovIDummerRPembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialLancet Oncol201516890891826115796
   PubMed Web of Science ®Google Scholar
• LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med20153731233426027431
   PubMed Web of Science ®Google Scholar
• BoussiotisVAMolecular and biochemical aspects of the PD-1 checkpoint pathwayN Engl J Med2016375181767177827806234
   PubMed Web of Science ®Google Scholar
• FrenelJSTourneauCLNeilBHPembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 studyJ Clin Oncol2016Suppl 345515
   Web of Science ®Google Scholar
• OttPABangYJRigaudDBPembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 studyJ Clin Oncol2016Suppl 345581
   Web of Science ®Google Scholar
• GajewskiTFThe next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed tumor microenvironmentSemin Oncol201542466367126320069
   PubMed Web of Science ®Google Scholar
• CorralesLMatsonVFloodBSprangerSGajewskiTFInnate immune signaling and regulation in cancer immunotherapyCell Res20172719610827981969
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• PlimackERBellmuntJGuptaSSafety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b studyLancet Oncol201718221222028081914
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBMcDermottDFNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191803181326406148
   PubMed Web of Science ®Google Scholar
• WeberJSD’AngeloSPMinorDNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialLancet Oncol201516437538425795410
   PubMed Web of Science ®Google Scholar
• GoldenEBFrancesDPellicciottaIDemariaSHelen Barcellos-HoffMFormentiSCRadiation fosters dose-dependent and chemotherapy-induced immunogenic cell deathOncoimmunology20143e2851825071979
   PubMed Web of Science ®Google Scholar
• FormentiSCDemariaSCombining radiotherapy and cancer immunotherapy: a paradigm shiftJ Natl Cancer Inst2013105425626523291374
   PubMed Web of Science ®Google Scholar
• SpiottoMFuYXWeichselbaumRRThe intersection of radiotherapy and immunotherapy: mechanisms and clinical implicationsSci Immunol201613EAAG126628018989
   PubMed Web of Science ®Google Scholar
• DengLLiangHBurnetteBIrradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in miceJ Clin Invest2014124268769524382348
   PubMed Web of Science ®Google Scholar
• Twyman-Saint VictorCRechAJMaityARadiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerNature2015520754737337725754329
   PubMed Web of Science ®Google Scholar
• PostowMACallahanMKBarkerCAImmunologic correlates of the abscopal effect in a patient with melanomaN Engl J Med20123661092593122397654
   PubMed Web of Science ®Google Scholar
• GoldenEBDemariaSSchiffPBChachouaAFormentiSCAn abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancerCancer Immunol Res20131636537224563870
   PubMed Web of Science ®Google Scholar
• DewanMZGallowayAEKawashimaNFractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibodyClin Cancer Res200915175379538819706802
   PubMed Web of Science ®Google Scholar
• SchaueDRatikanJAIwamotoKSMcBrideWHMaximizing tumor immunity with fractionated radiationInt J Radiat Oncol Biol Phys20128341306131022208977
   PubMed Web of Science ®Google Scholar
• RibasAPuzanovIDummerRPembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialLancet Oncol201516890891826115796
   PubMed Web of Science ®Google Scholar
• McDermottDFDrakeCGSznolMSurvival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumabJ Clin Oncol201533182013202025800770
   PubMed Web of Science ®Google Scholar
• MotzerRJRiniBIMcDermottDFNivolumab for metastatic renal cell carcinoma: results of a randomized phase II trialJ Clin Oncol201533131430143725452452
   PubMed Web of Science ®Google Scholar
• RanckMCGoldenDWCorbinKSStereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinomaAm J Clin Oncol201336658959522868242
   PubMed Web of Science ®Google Scholar
• SalamaJKHasselleMDChmuraSJStereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic diseaseCancer2012118112962297022020702
   PubMed Web of Science ®Google Scholar
• StinauerMAKavanaghBDSchefterTEStereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local controlRadiat Oncol201163421477295
   PubMed Web of Science ®Google Scholar
• ShaverdianNLisbergAEBornazyanKPrevious radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEY-NOTE-001 phase 1 trialLancet Oncol201718789590328551359
   PubMed Web of Science ®Google Scholar
• KwonEDDrakeCGScherHICA184-043 InvestigatorsIpilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialLancet Oncol201415770071224831977
   PubMed Web of Science ®Google Scholar
• SlovinSFHiganoCSHamidOIpilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II studyAnn Oncol20132471813182123535954
   PubMed Web of Science ®Google Scholar
• Howlader NNAKrapchoMGarshellJSEER Cancer Statistics Review19752013National Cancer InstituteBethesda, MD2016
   Google Scholar
• MungerKPhelpsWCBubbVHowleyPMSchlegelRThe E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytesJ Virol19896310441744212476573
   PubMed Web of Science ®Google Scholar
• KimJYKimJYKimJHYoonMSKimJKimYSCurative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastasesInt J Radiat Oncol Biol Phys201284374174722898382
   PubMed Web of Science ®Google Scholar
• BeriwalSGanGNHeronDEEarly clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancerInt J Radiat Oncol Biol Phys200768116617117321070
   PubMed Web of Science ®Google Scholar
• TrimbleCLMorrowMPKraynyakKASafety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trialLancet2015386100082078208826386540
   PubMed Web of Science ®Google Scholar
• EskanderRNTewariKSImmunotherapy: an evolving paradigm in the treatment of advanced cervical cancerClin Ther2015371203825592089
   PubMed Web of Science ®Google Scholar
• van der BurgSHArensROssendorpFvan HallTMeliefCJVaccines for established cancer: overcoming the challenges posed by immune evasionNat Rev Cancer201616421923326965076
   PubMed Web of Science ®Google Scholar
• AnsellSMLesokhinAMBorrelloIPD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphomaN Engl J Med2015372431131925482239
   PubMed Web of Science ®Google Scholar
• HowittBESunHHRoemerMGGenetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulvaJAMA Oncol20162451852226913631
   PubMed Web of Science ®Google Scholar
• HeerenAMKosterBDSamuelsSHigh and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancerCancer Immunol Res201531485825361854
   PubMed Web of Science ®Google Scholar
• HeerenAMde BoerEBleekerMCNodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment areaOncotarget2015632324843249326431490
   PubMedGoogle Scholar
• Lyford-PikeSPengSYoungGDEvidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinomaCancer Res20137361733174123288508
   PubMed Web of Science ®Google Scholar
• KangTHMaoCPLeeSYChemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunityCancer Res20137382493250423418322
   PubMed Web of Science ®Google Scholar
• van der SluisTCvan DuikerenSHuppelschotenSVaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell deathClin Cancer Res201521478179425501579
   PubMed Web of Science ®Google Scholar
• KhagiYKurzrockRPatelSPNext generation predictive biomarkers for immune checkpoint inhibitionCancer Metastasis Rev201736117919027873079
   PubMed Web of Science ®Google Scholar
• LheureuxSButlerMOClarkeBA phase I/II study of ipilimumab in women with metastatic or recurrence cervical carcinoma: A study of the Princess Margaret and Chicago N01 ConsortiaJ Clin Oncol201533 Suppl3061
   Web of Science ®Google Scholar
• ViswanathanANBeriwalSDe Los SantosJFAmerican Brachytherapy SocietyAmerican Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapyBrachytherapy2012111475222265437
   PubMed Web of Science ®Google Scholar
• HodgeJWSharpHJGameiroSRAbscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiationCancer Biother Radiopharm2012271122222283603
   PubMed Web of Science ®Google Scholar
• RichNDahleCModrickJBuattiJWeinerGBrachytherapy combined with CpG ODN enhances development of a tumor antigen-specific CD8 responseBlood2004104114635
   Web of Science ®Google Scholar
• NesslingerNJSahotaRAStoneBStandard treatments induce antigen-specific immune responses in prostate cancerClin Cancer Res20071351493150217332294
   PubMed Web of Science ®Google Scholar
• del CarmenMGBirrerMSchorgeJOUterine papillary serous cancer: a review of the literatureGynecol Oncol201212736516612300148
   PubMed Web of Science ®Google Scholar
• HamiltonCACheungMKOsannKUterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancersBr J Cancer200694564264616495918
   PubMed Web of Science ®Google Scholar
• NemaniDMitraNGuoMLinLAssessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysisGynecol Oncol20081111828818674808
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkKandothCSchultzNIntegrated genomic characterization of endometrial carcinomaNature20134977447677323636398
   PubMed Web of Science ®Google Scholar
• ChurchDNStellooENoutRAPrognostic significance of POLE proofreading mutations in endometrial cancerJ Natl Cancer Inst2015107140225505230
   PubMedGoogle Scholar
• HermanJGUmarAPolyakKIncidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinomaProc Natl Acad Sci U S A19989512687068759618505
   PubMed Web of Science ®Google Scholar
• HowittBEShuklaSAShollLMAssociation of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1JAMA Oncol2015191319132326181000
   PubMed Web of Science ®Google Scholar
• LeDTUramJNWangHPD-1 blockade in tumors with mismatch-repair deficiencyN Engl J Med2015372262509252026028255
   PubMed Web of Science ®Google Scholar
• BelloneSCentrittoFBlackJPolymerase epsilon (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patientsGynecol Oncol20151381111725931171
   PubMed Web of Science ®Google Scholar
• BelloneSBignottiELonardiSPolymerase epsilon (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitroGynecol Oncol2017144114615227894751
   PubMed Web of Science ®Google Scholar
• MehnertJMPandaAZhongHImmune activation and response to pembrolizumab in POLE-mutant endometrial cancerJ Clin Invest201612662334234027159395
   PubMed Web of Science ®Google Scholar
• SantinADBelloneSBuzaNRegression of chemotherapy-resistant polymerase epsilon (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumabClin Cancer Res201622235682568727486176
   PubMed Web of Science ®Google Scholar
• FlemingGFEmensLAEderJPClinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC)J Clin Oncol201735(15)(Suppl)5585
   Web of Science ®Google Scholar
• ChanJKBradyMFPensonRTWeekly vs. every-3-week paclitaxel and carboplatin for ovarian cancerN Engl J Med2016374873874826933849
   PubMed Web of Science ®Google Scholar
• PignataSScambiaGKatsarosDGynecologic Cancer Inter Group (GCIG) InvestigatorsCarboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trialLancet Oncol201415439640524582486
   PubMed Web of Science ®Google Scholar
• KatsumataNYasudaMIsonishiSJapanese Gynecologic Oncology GroupLong-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trialLancet Oncol201314101020102623948349
   PubMed Web of Science ®Google Scholar
• RedmanCWMouldJWarwickJThe west midlands epithelial ovarian cancer adjuvant therapy trialClin Oncol (R Coll Radiol)199351158424908
   PubMedGoogle Scholar
• ChiaraSContePFranzonePHigh-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapyAm J Clin Oncol199417172768311013
   PubMed Web of Science ®Google Scholar
• BruzzoneMRepettoLChiaraSChemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second lookGynecol Oncol19903833923952227553
   PubMed Web of Science ®Google Scholar
• LawtonFLuesleyDBlackledgeGA randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West Midlands Ovarian Cancer Group Trial IIClin Oncol (R Coll Radiol)199021492261388
   PubMedGoogle Scholar
• SorbeBSwedish-Norgewian Ovarian Cancer Study GConsolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatmentInt J Gynecol Cancer200313327828612801256
   PubMed Web of Science ®Google Scholar
• EinhornNTropeCRidderheimMBomanKSorbeBCavallin-StahlEA systematic overview of radiation therapy effects in ovarian cancerActa Oncol2003425–656256614596514
   PubMed Web of Science ®Google Scholar
• RochetNLindelKKatayamaSIntensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer: four-year outcomesStrahlenther Onkol2015191758258925786589
   PubMed Web of Science ®Google Scholar
• RochetNKieserMSterzingFPhase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 StudyBMC Cancer2011114121276234
   PubMed Web of Science ®Google Scholar
• RochetNSterzingFJensenADIntensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I studyInt J Radiat Oncol Biol Phys20107651382138919628341
   PubMed Web of Science ®Google Scholar
• CurielTJCoukosGZouLSpecific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalNat Med200410994294915322536
   PubMed Web of Science ®Google Scholar
• SatoEOlsonSHAhnJIntraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancerProc Natl Acad Sci U S A200510251185381854316344461
   PubMed Web of Science ®Google Scholar
• WoutersMCKomdeurFLWorkelHHTreatment regimen, surgical outcome, and T-cell differentiation influence prognostic benefit of tumor-infiltrating lymphocytes in high-grade serous ovarian cancerClin Cancer Res201622371472426384738
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkIntegrated genomic analyses of ovarian carcinomaNature2011474735360961521720365
   PubMed Web of Science ®Google Scholar
• KonecnyGEWangCHamidiHPrognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancerJ Natl Cancer Inst201410610dju24925269487
   PubMedGoogle Scholar
• LiuBNashJRunowiczCSwedeHStevensRLiZOvarian cancer immunotherapy: opportunities, progresses and challengesJ Hematol Oncol20103720146807
   PubMed Web of Science ®Google Scholar
• HodiFSButlerMObleDAImmunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsProc Natl Acad Sci U S A200810583005301018287062
   PubMed Web of Science ®Google Scholar
• HamanishiJMandaiMIkedaTSafety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancerJ Clin Oncol201533344015402226351349
   PubMed Web of Science ®Google Scholar
• VargaAPiha-PaulSAOttPAAntitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib studyJ Clin Oncol201533(15)(Suppl)5510
   Web of Science ®Google Scholar
• DisisMLPatelMRPantSAvelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trialJ Clin Oncol201533(15)(Suppl)5509
   Web of Science ®Google Scholar
• KunosCASillMWBuekersTELow-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a Phase I study of the Gynecologic Oncology GroupGynecol Oncol2011120222422821075438
   PubMed Web of Science ®Google Scholar